Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma Katelyn N. PurvisHope D. SwansonJamie E. Flerlage Original Article 18 May 2023 Pages: 1 - 6
Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database Mitsuaki OuraFumiya OguroYoshitaka Nishikawa Original Article 19 May 2023 Pages: 7 - 14
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma Drew W. RascoTheresa MedinaAnthony J. Olszanski Original Article Open access 23 May 2023 Pages: 15 - 28
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02) Tsukasa HasegawaRyo AriyasuMakoto Nishino Original Article 27 May 2023 Pages: 29 - 37
ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative Amanda B. KaganBlake S. MosesCurt I. Civin Original Article 30 May 2023 Pages: 39 - 50
Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia Minu SinghDivya BhaskarAmita Trehan Original Article 31 May 2023 Pages: 51 - 56
A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis Philipp KönigRoman ZhulenkoGerd Bendas Original Article Open access 05 June 2023 Pages: 57 - 69
Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis Lan HongXiuzhen WangGenhai Zhu Original Article Open access 05 June 2023 Pages: 71 - 81
